The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2001-1326
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies ; volume:8 ; number:1 ; day:18 ; month:3 ; year:2019 ; pages:1-14 ; date:12.2019
Clinical and translational medicine ; 8, Heft 1 (18.3.2019), 1-14, 12.2019
- Urheber
-
Gong, Jun
Chehrazi-Raffle, Alexander
Placencio-Hickok, Veronica
Guan, Michelle
Hendifar, Andrew
Salgia, Ravi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40169-019-0225-x
- URN
-
urn:nbn:de:101:1-2019041102401879128311
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gong, Jun
- Chehrazi-Raffle, Alexander
- Placencio-Hickok, Veronica
- Guan, Michelle
- Hendifar, Andrew
- Salgia, Ravi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Immune Checkpoint Blockers and Ovarian Cancer
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
Therapeutic RIG-I activation enhances survival and induces sensitivity to immune checkpoint blockade therapy in preclinical models of AML
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Immune Checkpoint Blockers and Ovarian Cancer
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
Therapeutic RIG-I activation enhances survival and induces sensitivity to immune checkpoint blockade therapy in preclinical models of AML
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Immune Checkpoint Blockers and Ovarian Cancer
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review